Summit Therapeutics SMMT Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's change in accrued liabilities?
- Summit Therapeutics (SMMT) reported change in accrued liabilities of $12.22M in Q1 2026.
- How has Summit Therapeutics's change in accrued liabilities changed year-over-year?
- Summit Therapeutics's change in accrued liabilities increased by 658.4% year-over-year, from $1.61M to $12.22M.
- What is the long-term trend for Summit Therapeutics's change in accrued liabilities?
- Over 3 years (2021 to 2025), Summit Therapeutics's change in accrued liabilities has grown at a 33.0% compound annual growth rate (CAGR), from $5.49M to $12.93M.
- What does change in accrued liabilities mean?
- The change in expenses that have been recognized but not yet paid out in cash.
- How do you interpret change in accrued liabilities?
- An increase represents a non-cash expense accrual that preserves cash, while a decrease indicates the settlement of these obligations.
- How does change in accrued liabilities compare across companies?
- Standard across all industries; highly relevant for R&D-heavy firms with significant accrued clinical research costs.